283 related articles for article (PubMed ID: 25759549)
21. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer.
Shi L; Zhou Q; Wu J; Ji M; Li G; Jiang J; Wu C
Cancer Immunol Immunother; 2012 Dec; 61(12):2251-9. PubMed ID: 22674056
[TBL] [Abstract][Full Text] [Related]
22. Impact of culture medium on the expansion of T cells for immunotherapy.
Sato K; Kondo M; Sakuta K; Hosoi A; Noji S; Sugiura M; Yoshida Y; Kakimi K
Cytotherapy; 2009; 11(7):936-46. PubMed ID: 19903105
[TBL] [Abstract][Full Text] [Related]
23. Gastric cancer and the epoch of immunotherapy approaches.
Niccolai E; Taddei A; Prisco D; Amedei A
World J Gastroenterol; 2015 May; 21(19):5778-93. PubMed ID: 26019442
[TBL] [Abstract][Full Text] [Related]
24. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.
Li R; Wang C; Liu L; Du C; Cao S; Yu J; Wang SE; Hao X; Ren X; Li H
Cancer Immunol Immunother; 2012 Nov; 61(11):2125-33. PubMed ID: 22581306
[TBL] [Abstract][Full Text] [Related]
25. High expression of CD11c indicates favorable prognosis in patients with gastric cancer.
Wang Y; Xu B; Hu WW; Chen LJ; Wu CP; Lu BF; Shen YP; Jiang JT
World J Gastroenterol; 2015 Aug; 21(31):9403-12. PubMed ID: 26309367
[TBL] [Abstract][Full Text] [Related]
26. Expression of signal transducing T-cell receptor zeta molecules after adoptive immunotherapy in patients with gastric and colon cancer.
Kono K; Ichihara F; Iizuka H; Sekikawa T; Matsumoto Y
Int J Cancer; 1998 Oct; 78(3):301-5. PubMed ID: 9766562
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.
Kono K; Takahashi A; Ichihara F; Amemiya H; Iizuka H; Fujii H; Sekikawa T; Matsumoto Y
Clin Cancer Res; 2002 Jun; 8(6):1767-71. PubMed ID: 12060615
[TBL] [Abstract][Full Text] [Related]
28. Novel immunological and nutritional-based prognostic index for gastric cancer.
Sun KY; Xu JB; Chen SL; Yuan YJ; Wu H; Peng JJ; Chen CQ; Guo P; Hao YT; He YL
World J Gastroenterol; 2015 May; 21(19):5961-71. PubMed ID: 26019461
[TBL] [Abstract][Full Text] [Related]
29. Long-term intravenous administration of activated autologous lymphocytes for cancer patients does not induce antinuclear antibody and rheumatoid factor.
Yamaguchi T; Bamba K; Kitayama A; Kuroiwa Y; Yoshimatsu K; Shimakawa T; Ogawa K; Sekine T; Shimizu N; Yamamoto K
Anticancer Res; 2004; 24(4):2423-9. PubMed ID: 15330194
[TBL] [Abstract][Full Text] [Related]
30. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.
Liu J; Li H; Cao S; Zhang X; Yu J; Qi J; An X; Yu W; Ren X; Hao X
J Immunother; 2014; 37(2):115-22. PubMed ID: 24509174
[TBL] [Abstract][Full Text] [Related]
31. Predictive significance of T cell subset changes during
Huang L; Qiao G; Morse MA; Wang X; Zhou X; Wu J; Hobeika A; Ren J; Lyerly HK
Oncol Lett; 2019 Dec; 18(6):5717-5724. PubMed ID: 31788044
[TBL] [Abstract][Full Text] [Related]
32. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.
Gulubova M; Manolova I; Kyurkchiev D; Julianov A; Altunkova I
APMIS; 2009 Dec; 117(12):870-9. PubMed ID: 20078551
[TBL] [Abstract][Full Text] [Related]
33. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
34. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy.
Meehan KR; Wu J; Webber SM; Barber A; Szczepiorkowski ZM; Sentman C
Cytotherapy; 2008; 10(1):30-7. PubMed ID: 18202972
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients.
Zhao H; Fan Y; Li H; Yu J; Liu L; Cao S; Ren B; Yan F; Ren X
Cancer Biother Radiopharm; 2013 May; 28(4):303-9. PubMed ID: 23506427
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
38. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas.
Weng DS; Zhou J; Zhou QM; Zhao M; Wang QJ; Huang LX; Li YQ; Chen SP; Wu PH; Xia JC
J Immunother; 2008 Jan; 31(1):63-71. PubMed ID: 18157013
[TBL] [Abstract][Full Text] [Related]
39. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
40. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering.
Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS
Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
